Results 151 to 160 of about 60,520 (273)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

, 2015
Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany ...
McDonnell DP, E, Berggren L, Deix C, Tóth Á, An   +5 more
core  

Olanzapine as a cause of urinary incontinence: a case report.

Iranian Journal of Psychiatry, 2012
Olanzapine, an atypical antipsychotic, is one of the most commonly used antipsychotics. Though olanzapine is commonly associated with endocrine side effects, it is generally well tolerated by most patients and is rarely associated with urinary ...
Mobolaji Usman Dada, Lateef Olutoyin Oluwole, Patrick T Adegun, Peter O Tareo   +3 more
doaj  

Olanzapine and venous thromboembolism

, 2003
Clozapine has recently been associated with venous thromboembolism. The aim of this study was to describe three elderly patients in whom olanzapine therapy was associated with venous thromboembolism.
Hagg, S, Spigset, O, Tätting, Per
core  

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

, 2008
Giorgio L Colombo1, Mauro Caruggi2, Sergio Di Matteo1, Alessandro Rossi31S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy; 3Università de L’Aquila,
Giorgio L Colombo, Alessandro Rossi, Sergio Di Matteo, Mauro Caruggi   +3 more
core  

Characterising the pharmacokinetics of olanzapine in patients with anorexia nervosa (TORPEDO): protocol for a multicentre cross-sectional study. [PDF]

BMJ Open
Liang J, Dierckx B, Dieleman GC, Bosch TM, Koch BCP, De Winter BCM.   +5 more
europepmc   +1 more source

Real-World Analysis of Olanzapine and Functional Outcomes in Outpatient Cancer Rehabilitation. [PDF]

Cancers (Basel)
Karras I, Beck K, Barber A, Abplanalp K, Roy I.   +4 more
europepmc   +1 more source

The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.

Journal of Clinical Investigation, 2017
C. Lord, S. Wyler, Rong Wan, C. Castorena, N. Ahmed, D. Mathew, Syann Lee, Chen Liu, J. Elmquist   +8 more
semanticscholar   +1 more source

Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia. [PDF]

Hum Psychopharmacol
Chen X, Ma J, Xuan X, Huang M, Yang X, Huang B.   +5 more
europepmc   +1 more source

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]

, 2015
Wani RA, Dar MA, Chandel RK, et al Title of paper should have been “Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a randomized, open-label study&rdquo ...
Hussain A, Rather YH, Malla AA, Haq I, Wani RA, Chandel RK, Dar MA   +6 more
core  

Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders. [PDF]

Eur J Clin Pharmacol
Hersleth V, Spigset O, Weider S, Koch E, Andreassen OA, Lydersen S, Fjukstad KK.   +6 more
europepmc   +1 more source